Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer

Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer

Source: 
Memorial Sloan Kettering Cancer Center
snippet: 

The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer.